Immunogenicity of RSV F DNA Vaccine in BALB/c Mice.
Respiratory syncytial virus (RSV) causes severe acute lower respiratory tract disease leading to numerous hospitalizations and deaths among the infant and elderly populations worldwide. There is no vaccine or a less effective drug available against RSV infections. Natural RSV infection stimulates the Th1 immune response and activates the production of neutralizing antibodies, while earlier vaccine trials that used UV-inactivated RSV exacerbated the disease due to the activation of the allergic Th2 response. With a focus on Th1 immunity, we developed a DNA vaccine containing the native RSV fusion (RSV F) protein and studied its immune response in BALB/c mice. High levels of RSV specific antibodies were induced during subsequent immunizations. The serum antibodies were able to neutralize RSV in vitro. The RSV inhibition by sera was also shown by immunofluorescence analyses. Antibody response of the RSV F DNA vaccine showed a strong Th1 response. Also, sera from RSV F immunized and RSV infected mice reduced the RSV infection by 50% and 80%, respectively. Our data evidently showed that the RSV F DNA vaccine activated the Th1 biased immune response and led to the production of neutralizing antibodies, which is the desired immune response required for protection from RSV infections.
Center for NanoBiotechnology Research, Alabama State University, Montgomery, AL, USA; Faculty of Engineering, Bioengineering Department, Celal Bayar University, Muradiye, Manisa, Turkey.
Erdal
0000-0001-7281-3906
E
Eroglu
College of Medicine, University of South Alabama, Mobile, AL, USA.
Ankur
0000-0002-0536-2401
A
Singh
Center for NanoBiotechnology Research, Alabama State University, Montgomery, AL, USA.
Swapnil
0000-0001-9139-5375
S
Bawage
Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Pooja M
0000-0001-8170-3602
PM
Tiwari
Center for NanoBiotechnology Research, Alabama State University, Montgomery, AL, USA.
Komal
0000-0002-5280-8920
K
Vig
Center for NanoBiotechnology Research, Alabama State University, Montgomery, AL, USA.
Shreekumar R
0000-0002-0431-8628
SR
Pillai
Center for NanoBiotechnology Research, Alabama State University, Montgomery, AL, USA.
Vida A
0000-0003-1409-5605
VA
Dennis
Center for NanoBiotechnology Research, Alabama State University, Montgomery, AL, USA.
Shree R
0000-0002-3571-2222
SR
Singh
Int J Antimicrob Agents. 2015 Mar;45(3):234-7
25684638
Int J Nanomedicine. 2013;8:1403-15
23610520
Vaccine. 1990 Oct;8(5):497-502
2251875
Proc Natl Acad Sci U S A. 1984 Dec;81(24):7683-7
6096849
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9619-24
21586636
J Clin Virol. 2009 Apr;44(4):287-91
19233722
Vaccine. 2004 Jun 2;22(17-18):2248-60
15149784
Vet Res. 2007 Mar-Apr;38(2):153-80
17257568
J Virol. 1997 May;71(5):4055-61
9094683
Pediatr Infect Dis J. 2011 Jun;30(6):510-7
21487331
J Infect. 2002 Jul;45(1):18-24
12217726
Vaccine. 2007 Oct 10;25(41):7271-9
17825960
N Engl J Med. 2014 Aug 21;371(8):711-22
25140957
Vaccine. 2014 Oct 7;32(44):5866-74
25173478
Nature. 2001 Apr 19;410(6831):1002-7
11309631
Lancet. 2012 Dec 15;380(9859):2095-128
23245604
Vaccine. 1993 Nov;11(14):1415-23
7508665
J Med Microbiol. 2003 Oct;52(Pt 10):893-6
12972584
J Virol. 2007 Dec;81(24):13710-22
17928349
Vaccine. 2004 Mar 29;22(11-12):1465-74
15063570
Vaccine. 2009 Mar 10;27(11):1758-63
19186202
Virus Res. 2009 Oct;145(1):39-47
19540885
Immunol Lett. 2011 May;136(2):122-9
21195729
J Gen Virol. 2001 Nov;82(Pt 11):2663-74
11602778
Arch Dis Child. 2014 May;99(5):469-73
24464977
Curr Opin Immunol. 2000 Aug;12(4):442-7
10899026
Immunol Lett. 2009 Aug 15;125(2):79-85
19539648
J Virol. 1996 May;70(5):2852-60
8627759
Vaccine. 2016 Jan 4;34(2):190-7
26100926
Science. 2013 Nov 1;342(6158):592-8
24179220
Lancet. 2010 May 1;375(9725):1545-55
20399493
J Virol. 2015 Sep;89(18):9499-510
26157122
Vaccine. 2007 Aug 14;25(33):6211-23
17629376
PLoS Pathog. 2015 Jul 10;11(7):e1005035
26161532
J Immunol. 2003 Feb 15;170(4):2037-45
12574374